Aprea Therapeutics, Inc. (APRE)
NASDAQ: APRE · Real-Time Price · USD
1.230
+0.030 (2.50%)
At close: Nov 7, 2025, 4:00 PM EST
1.230
0.00 (0.00%)
After-hours: Nov 7, 2025, 4:10 PM EST
Aprea Therapeutics Revenue
Aprea Therapeutics had revenue of $118.11K in the quarter ending June 30, 2025, a decrease of -78.97%. This brings the company's revenue in the last twelve months to $841.01K, down -34.07% year-over-year. In the year 2024, Aprea Therapeutics had annual revenue of $1.50M with 157.63% growth.
Revenue (ttm)
$841.01K
Revenue Growth
-34.07%
P/S Ratio
8.77
Revenue / Employee
$105,127
Employees
8
Market Cap
7.17M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.50M | 919.35K | 157.63% |
| Dec 31, 2023 | 583.23K | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 56.50B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
APRE News
- 14 days ago - Aprea Therapeutics Provides Clinical Update from ACESOT-1051 Trial Showing Early Signals of Activity for WEE1 Kinase Inhibitor APR-1051 - GlobeNewsWire
- 23 days ago - Aprea Therapeutics Establishes Recommended Phase 2 Dose (RP2D) for ATRN-119, Considering Combination Therapies - GlobeNewsWire
- 24 days ago - Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics - GlobeNewsWire
- 2 months ago - Aprea Therapeutics to Present at H.C. Wainwright Global Investment Conference - GlobeNewsWire
- 3 months ago - Aprea Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Clinical Update - GlobeNewsWire
- 4 months ago - Aprea Reports Anti-Proliferative Results and Promising Early-Stage Clinical Data for Next-Generation WEE1 Inhibitor, APR-1051, in HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Collaboration with MD Anderson Cancer Center - GlobeNewsWire
- 6 months ago - Aprea Therapeutics Reports First Quarter 2025 Financial Results and Provides a Clinical Update - GlobeNewsWire
- 7 months ago - Aprea Therapeutics Announces Dosing of Patient with HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Ongoing ACESOT-1051 Trial - GlobeNewsWire